Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 5/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803139 | 0.76 | KMT2A (0.50) | MEN1KMT2ANR1H3SCN2APIM3 | |
| SCHEMBL725608 | 0.76 | NR1H3 (0.67) | MEN1KMT2ANR1H3SCN2APIM3 | |
| SCHEMBL4649471 | 0.73 | KMT2A (0.78) | MEN1KMT2ANR1H3SCN2ACA12 | |
| Hydrochloric Acid SCHEMBL8828253 | 0.72 | KMT2A (0.48) | MEN1KMT2ANR1H3SCN2ACA12 | |
| SCHEMBL9905226 | 0.72 | NOTUM (0.46) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL19773976 | 0.71 | KMT2A (0.68) | MEN1KMT2ANR1H3SCN2ACA12 | |
| N-Phenyl-Phthalimide SCHEMBL29819622 | 0.71 | KMT2A (0.68) | MEN1KMT2ANR1H3SCN2ACA12 | |
| N-Phenyl-Phthalimide SCHEMBL123618 | 0.71 | KMT2A (0.68) | MEN1KMT2ANR1H3SCN2ACA12 | |
| SCHEMBL3347164 | 0.69 | CDK8 (0.49) | MEN1KMT2AHTT | |
| SCHEMBL8474317 | 0.69 | NR1H3 (0.64) | MEN1KMT2ANR1H3SCN2APIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-06-17 | — | — | US | disclosed |
| WO-2017161119-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | CRBN, CD4, CD74 | MEN1 2966/4885KMT2A 3583/4885NR1H3 717/4885 |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | CD4, GZMB, CRBN | MEN1 1005/4885KMT2A 3183/4885NR1H3 1760/4885 |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | MEN1 738/4885KMT2A 3074/4885NR1H3 1392/4885 |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, GZMB, CRBN | MEN1 1005/4885KMT2A 3183/4885NR1H3 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.